Ultragenyx Pharmaceutical Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $673.0M | $560.0M | $434.0M | $363.3M | $351.4M |
| Operating income | -$535.0M | -$536.0M | -$569.0M | -$648.9M | -$381.7M |
| Cash from operations | -$466.0M | -$414.0M | -$475.0M | -$380.5M | -$338.7M |
| Capital expenditure | $6.0M | $7.0M | $44.0M | $116.1M | $73.1M |
| Free cash flow | -$472.0M | -$421.0M | -$519.0M | -$496.6M | -$411.8M |
| Total assets | $1.5B | $1.5B | $1.5B | $1.5B | $1.5B |
| Total liabilities | $1.6B | $1.2B | $1.2B | $1.2B | $599.8M |
Shares outstanding 98.5M · Free float 91.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.